Hispanic Heritage Month and Psychedelics
Celebrate National Hispanic Heritage Month by expressing gratitude for Hispanic and Latinx visionaries, researchers, community members, and others who have expanded awareness about psychedelics. Taking …
Participant Safety in Psychedelic Therapy
All stakeholders at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) are committed to providing quality and comprehensive training and supervision …
Protected: MAPS and Founder Rick Doblin Submit Written Comments to FDA on Psychedelic-Assisted Therapy Standards
There is no excerpt because this is a protected post.
2026 Third Quarter — Legislative Wrap Up
Since the beginning of 2026, at least 23 states have introduced psychedelic legislation, signaling continued momentum and openness in how local and federal leaders address mental health, substance use …
MAPS and International Alliance of Psychedelic Therapy Practitioners Announce Partnership to Advance Training for Psychedelic-Assisted Therapy
Washington, D.C., October 5, 2026 – The Multidisciplinary Association for Psychedelic Studies (MAPS) announced a new strategic partnership with the International Alliance of Psychedelic Therapy Practitioners …
Statement on DEA attempt to reschedule five tryptamines
Last week, the DEA moved to place five little-known psychedelic compounds — 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT — into Schedule I of the Controlled Substances Act. It’s the …
MAPS Attends Historic FDA Hearing on Psychedelics
Washington, D.C., September 17, 2026 — The FDA’s September 14 hearing marked one of the most consequential regulatory moments for psychedelic-assisted therapy to date. The Multidisciplinary Association …
University of Miami’s Gift of 1994 Ibogaine IND to HHS Sets a Standard for Open Science
Washington, D.C., August 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS)has welcomed the announcement that the University of Miami has gifted the federal government its 1994 …
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an August 9 report by Psychedelic Alpha indicating that Resilient Pharmaceuticals (formerly …
MAPS Announces Agreement with UAB
MAPS can now share we have finalized a clinical trial agreement with the University of Alabama, Birmingham, making UAB the first official site for the MJP2 study of inhaled cannabis in the treatment of …
Clinical-Trial Cannabis and Placebo has Been Shipped
Following the issuance of an import permit by Health Canada in June 2026, Research Triangle Institute, the contracted licensed distributor for the National Institute on Drug Abuse (NIDA) Drug Supply Program, …
2026 Second Quarter — Policy & Advocacy Wrap Up
Policy & Advocacy Updates This quarter marked an exciting period of growth and progress for MAPS’ Policy & Advocacy team. Through strategic partnerships, innovative research, coalition building, …